fullerene c60 has been researched along with Acute Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Djordjevic, A; Dragojevic-Simic, V; Jacevic, V; Kuca, K; Milic-Tores, V; Segrt, Z; Srdjenovic, B | 1 |
1 other study(ies) available for fullerene c60 and Acute Disease
| Article | Year |
|---|---|
Fullerenol nanoparticles prevents doxorubicin-induced acute hepatotoxicity in rats.
Topics: Acute Disease; Animals; Antineoplastic Agents; Body Weight; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Doxorubicin; Fullerenes; Lipid Peroxidation; Liver; Male; Nanoparticles; Rats; Rats, Wistar; Thiobarbituric Acid Reactive Substances | 2017 |